LLY Eli Lilly and Company logo

LLY Eli Lilly and Company

Healthcare
$1065.00+2.24%ClosedMarket Cap: $1.00T

As of 2026-05-25

Valuation

View Details

P/E (TTM)

43.01

PEG

0.45

P/B

30.54

P/S

13.88

EV/EBITDA

31.42

DCF Value

$534.09

FCF Yield

1.4%

Div Yield

0.6%

Margins & Returns

Gross Margin

83.5%

Operating Margin

45.9%

Net Margin

35.0%

ROE

101.3%

ROA

21.7%

ROIC

32.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$19.80B$7.40B$
Q4 null$19.29B$6.64B$
FY null$65.18B$20.64B$
Q3 null$17.60B$5.58B$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$1,263.74

Target (Median)

$1,280.00

Target Range

$1,070.00 - $1,400.00

6 Strong Buy18 Buy6 Hold1 Sell0 Strong Sell
BarclaysOverweight
2026-05-05
GuggenheimBuy
2026-05-05
Wolfe ResearchOutperform
2026-05-04
Cantor FitzgeraldOverweight
2026-05-01
Morgan StanleyOverweight
2026-04-10

Trading Activity

Insider Trades

View All
Sulzberger Gabrielledirector
SellTue May 19
LUCIANO JUAN Rdirector
SellTue May 19
Fyrwald J Erikdirector
SellTue May 19
Alvarez Ralphdirector
SellTue May 19
LILLY ENDOWMENT INCother: Former 10% Shareholder
SellThu May 07

Congress Trades

View All
Byron DonaldsBuy
Thu May 14
Gilbert CisnerosBuy
Mon May 11
Lizzie FletcherSell
Fri May 01
Gilbert CisnerosSell
Wed Apr 08
Angus KingSell
Tue Mar 24

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

US

Exchange

Beta

0.48

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Peers